Table 1.

The clinical and pathological characteristics of the four phenotypes of colorectal carcinoma, as defined by IHC. The figures are calculated as percentages within each phenotype. Cumulative percentage figures may exceed 100% due to rounding up to one significant figure.

	BRAF+ve/MSS	BRAF+ve/MSI	BRAF-ve/MSI	BRAF-ve/MSS
Total, No (%)	98 (7%)	183 (13%)	93 (7%)	1029 (73%)
Gender, No. (%)
Female	57 (58%)	136 (74%)	53 (57%)	468 (46%)
Male	41 (42%)	47 (26%)	40 (43%)	561 (55%)
Anatomic site, No. (%)
Cecum	20 (20%)	50 (28%)	33 (36%)	182 (18%)
Ascending colon	31 (32%)	64 (36%)	25 (27%)	110 (11%)
Transverse colon	16 (16%)	40 (23%)	21 (23%)	71 (7%)
Descending colon	9 (9%)	5 (3%)	4 (4%)	64 (6%)
Sigmoid colon	10 (10%)	14 (8%)	6 (6%)	276 (27%)
Rectum	12 (12%)	3 (2%)	4 (4%)	324 (32%)
Histologic grade, No. (%)
Low grade	57 (58%)	101 (57%)	63 (68%)	887 (86%)
High grade	41 (42%)	77 (43%)	30 (32%)	142 (14%)
pT stage, No. (%)
Tis	0 (0%)	0 (0%)	0 (0%)	1 (<1%)
T1	2 (2%)	7 (4%)	8 (9%)	80 (8%)
T2	6 (6%)	18 (10%)	9 (10%)	175 (17%)
T3	37 (38%)	112 (63%)	53 (57%)	515 (50%)
T4a	50 (51%)	30 (17%)	15 (16%)	217 (21%)
T4b	3 (3%)	11 (6%)	8 (9%)	41 (4%)
pN stage, No. (%)
N0	23 (24%)	114 (64%)	69 (74%)	558 (54%)
N1a	12 (12%)	21 (12%)	7 (8%)	130 (13%)
N1b	21 (22%)	18 (10%)	5 (5%)	125 (12%)
N1c	2 (2%)	3 (2%)	1 (1%)	34 (3%)
N2a	21 (22%)	13 (7%)	3 (3%)	103 (10%)
N2b	18 (19%)	9 (5%)	8 (9%)	79 (8%)
pM stage, No. (%)
Mx	88 (91%)	174 (98%)	91 (98%)	989 (96%)
M1a	4 (4%)	1 (<1%)	0 (0%)	20 (2%)
M1b	5 (5%)	3 (2%)	2 (2%)	20 (2%)
Overall stage, No. (%)
0	0 (0%)	0 (0%)	0 (0%)	1 (<1%)
I	4 (4%)	23 (13%)	14 (15%)	199 (19%)
IIA	11 (11%)	78 (44%)	43 (46%)	282 (27%)
IIB	8 (8%)	7 (4%)	9 (10%)	56 (5%)
IIC	2 (2%)	6 (3%)	3 (3%)	10 (1%)
IIIA	4 (4%)	3 (2%)	2 (2%)	46 (5%)
IIIB	31 (32%)	43 (24%)	9 (10%)	267 (26%)
IIIC	29 (30%)	14 (8%)	11 (12%)	127 (12%)
IVA	4 (4%)	1 (<1%)	0 (0%)	20 (2%)
IVB	5 (5%)	3 (2%)	2 (2%)	21 (2%)